Introduction
Rotavirus infection is the leading cause of severe diarrhoea in young children worldwide. 1 Since 2006, two eff ective rotavirus vaccines, RotaTeq (Merck and Co, PA, USA) and Rotarix (GSK Biologicals, Rixensart, Belgium), have been licensed, and they are recommended for use in all countries by WHO, particularly in those countries with high diarrhoea-related mortality in children younger than 5 years. [2] [3] [4] [5] [6] Substantial declines in morbidity and mortality attributable to rotavirus and all-cause diarrhoea have been recorded in high-income and middle-income countries that have introduced rotavirus vaccines so far. [7] [8] [9] [10] [11] [12] [13] Before rotavirus vaccines become more widely used in immunisation programmes, particularly in low-income countries where most deaths attributable to rotavirus infection happen, documenting the baseline number of deaths attributable to rotavirus infection is important.
These baseline estimates will help countries assess the potential value of vaccination and measure the eff ect of vaccines on mortality attributable to rotavirus infection.
By applying the proportion of severe cases of diarrhoea caused by rotavirus infection in children admitted to hospital to the estimated all-cause child deaths attrib utable to diarrhoea, WHO estimated 527 000 deaths in 2004 (range 475 000-580 000) in children younger than 5 years due to diarrhoea attributable to rotavirus infec tion.
14 New all-cause child mortality estimates released recently by the Child Health Epidemiology Reference Group of WHO and UNICEF 15 documented an overall decline in the mortality of children younger than 5 years with a change in the number of deaths due to diarrhoea from 1·8 million deaths in 2003 to 1·3 million in 2008. 15, 16 WHO estimated that there were 1·24 million deaths due to diarrhoea in children younger than 5 years in 2008. In view of these Although overall child diarrhoea-related mortality has declined over the past few years, this decline might not be uniform for all causes that contributed to these deaths. In particular, improvements in sanitation and hygiene have a large eff ect on diarrhoea caused by bacteria and parasites, which are mainly transmitted through contaminated food and water, and less of an eff ect on rotavirus diarrhoea, which is transmitted largely through person-to-person contact. [17] [18] [19] [20] [21] Thus, the decrease in overall diarrhoea-related mortality might be disproportionately due to decreases in bacterial and parasitic causes of diarrhoea. Indeed, a previous study 22 showed that although diarrhoea-related mortality has declined over the past three decades the proportion of severe diarrhoea attributable to rotavirus has increased. Since this previous study several reports of rotavirus disease burden have been published and the WHO-coordinated Global Rotavirus Surveillance Network has provided additional data on rotavirus disease burden in countries where data was not previously available.
Our objective is to update the rotavirus-related mortality estimate for children younger than 5 years on the basis of a review of recent published work and data from the WHO-coordinated rotavirus surveillance network.
23

Methods
Search strategy and selection criteria
To estimate the number of deaths attributable to rotavirus infection in 2008, we used the same methods as used in the previous rotavirus mortality estimate 14 and we followed the PRISMA guidelines. We searched PubMed, with the keyword "rotavirus" as our primary search term, to identify studies published between January, 2001, and January, 2011. We did not limit our search by language.
We limited our analysis to studies that met each of our criteria: a data collection midpoint in the year 2000 or later; done in full-year increments; and assessed diarrhoea due
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Sear-B Southeast Asia with low child mortality and low adult mortality Indonesia, Sri Lanka, Thailand We used quintiles of the distribution of child mortality to defi ne very low child mortality (fi rst quintile), low child mortality (second and third quintiles), and high child mortality (fourth and fi fth quintiles). 24 *After improvements in child mortality over recent years, Egypt meets criteria for inclusion in subregion Emr-B with low child mortality and low adult mortality. Egypt has been included in Emr-D for the presentation of subregional totals for mortality and burden to ensure comparability with previous editions of The World Health Report and other WHO publications. †Although Cambodia, Laos, and Papua New Guinea meet criteria for high child mortality, they have been included in the Wpr-B subregion with other developing countries of the western Pacifi c Region for reporting purposes. to rotavirus infection with an EIA or polyacrylamide gel electrophoresis, tests both sensitive and specifi c for identifying rotavirus infections, in at least 100 children younger than 5 years who were admitted to hospital with diarrhoea. We also included data from countries that participated in the WHO-coordinated Global Rotavirus Surveillance Network during 2009 and assessed rotavirusrelated diarrhoea with EIA in at least 100 children younger than 5 years who were admitted to hospital with diarrhoea. 23 For studies that included data from several countries or several sites within a single country we entered each country and site into our database as a separate study, where possible. For countries that have introduced rotavirus vaccine into their national immunisation programme, we excluded data subsequent to the introduction. Eligible studies were selected and data abstracted by a single author (JET) and reviewed by another author (UDP). For each study that satisfi ed our criteria we recorded the number of specimens tested, the number of positive results, and the proportion of positive results.
Data analysis
As with the previous assessments of mortality due to rotavirus infection, we constructed fi ve mortality groups on the basis of levels of child mortality (table 1) and region. We assigned countries to one of fi ve groups: group A (countries with very low child mortality), group B and C (countries with low child mortality), group D Americas (countries in the Americas with high child mortality), group D Asia (countries in Asia with high child mortality), and Group D and E Africa (countries in Africa with high child mortality). 14 We used quintiles of the distribution of child mortality to defi ne very low child mortality (fi rst quintile), low child mortality (second and third quintiles), and high child mortality (fourth and fi fth quintiles). 24 For each study, we identifi ed the proportion of children admitted to hospital with diarrhoea who tested positive for rotavirus. For each country group we used the DerSimonian-Laird randomeff ects method 25 to calculate a random-eff ect mean and 95% CI for the proportion of diarrhoea-related admis sions to hospital of children younger than 5 years who tested positive for rotavirus. We used a random-eff ect mean so that the contribution of each study to the estimated proportion would relate to both the (relative) sample size of the study (within-study variability) and the similarity with other studies (between-study variability). To obtain countryspecifi c estimates of rotavirus-related mortality, we fi rst multiplied the mean and 95% CI of the proportion of diarrhoea attributable to rotavirus for each group by the number of WHO-estimated child deaths caused by diarrhoea for each country in that group. We then summed these country-specifi c estimates to calculate rotavirusspecifi c child mortality for each group and worldwide. To derive the 95% CI for our worldwide mortality estimate, we did a bootstrap analysis with 10 000 samples from each stratum and then summed the total number of deaths across the groups. We ordered the resulting total number of rotavirus-related deaths in children younger than 5 years and selected the 250th and 9750th result.
We calculated the rotavirus-specifi c mortality rates per 100 000 children younger than 5 years with the UN Population Division estimates for the younger than 5 years population in 2008.
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Role of the funding source
There was no funding source for this study. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. 
Results
Specimens from 151 172 children younger than 5 years in 65 countries were tested as part of 131 studies that met our inclusion criteria (fi gure 1, table 2). Rotavirus detection rates ranged from 12% to 68% with a median of 39%. The highest mean detection rate (49%, 95% CI 34-64) was in group A, the countries with the lowest levels of child mortality, and the lowest mean detection rate (33%, 28-38) were in groups D and E in Africa (fi gure 2). We estimated that worldwide, each year, rotavirusrelated diar rhoea results in 453 000 deaths (95% CI 420 000-494 000) in children younger than 5 years, which accounts for 37% of diarrhoea-related deaths and 5% of all deaths in this age group. About 95% of these rotavirusrelated deaths happened in the 72 countries that are eligible to receive GAVI-supported vaccine. National estimates of rotavirus deaths in children younger than 5 years ranged from 99 000 in India to fewer than fi ve deaths in 74 countries. The greatest proportion of deaths was in India (22%). Five countries accounted for more than half of all rotavirus deaths: Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan (fi gure 3).
Rotavirus-specifi c mortality ranged from 518 deaths per 100 000 children younger than 5 years in Afghanistan to less than one death per 100 000 children in 63 countries (fi gure 4). Five countries (Afghanistan, Burundi, Chad, Mali, and Somalia) had rotavirus-specifi c mortality greater than 300 deaths per 100 000 children younger than 5 years.
Discussion
We estimated that, in 2008, rotavirus caused the deaths of 453 000 children younger than 5 years-ie, one of every 260 children born each year will die from diarrhoea caused by rotavirus infection by their fi fth birthday. Although the proportion of rotavirus detected in children admitted to hospital with diarrhoea was highest in developed countries, most rotavirus-related deaths were in developing countries in Africa and Asia. India alone accounted for a fi fth of these deaths (in part due to the size of its population younger than 5 years), but the greatest concentration of countries with high rates of rotavirus mortality was in sub-Saharan Africa.
Our estimate of deaths due to rotavirus-related diarrhoea in 2008 is somewhat lower than the previous estimate of 527 000 (95% CI 475 000-580 000) deaths in 2004, although the CIs of these estimates overlap. This diff erence is largely because of an overall decrease in diarrhoea-related deaths in children younger than 5 years from 1·8 million in 2003 to 1·2 million in 2008. 15, 16 However, we do not know what proportion of this decrease is due to a true decline in diarrhoea-related mortality and what proportion is due to a change in the methods used to estimate the number of diarrhoea-related deaths. The 32% decrease in all-cause diarrhoea-related deaths is not matched by a decrease of similar size in rotavirus-related deaths, which only declined overall by 14%. This diff erence is essentially because the published work we assessed for the period 2000 onwards estimates that 37% (95% CI 34-40) of diarrhoea-related deaths were associated with rotavirus compared with 29% (26-32) from the previous review of data from 1990 to 2005. The greater rotavirus detection rate partly off sets the decline in overall diarrhoea-related mortality. For example, in countries with high mortality in Asia, the overall decline in diarrhoea-related mortality from 763 000 to 452 000 deaths was largely compensated for by an increase in the median detection rate of rotavirus from 26% to 42%, resulting in relatively similar rotavirus-related mortality estimates (196 000 in 2004 and 188 000 in 2008).
Some issues should be considered when interpreting our estimates. First, because laboratory confi rmation of causes of diarrhoea-related deaths, particularly those in the community, is rare, we had to rely on the proportion of rotavirus-related admissions to hospital in all-cause diarrhoea-related admission as a proxy for the contri bution of rotavirus to all-cause diarrhoea-related deaths. Furthermore, we relied on country-specifi c diarrhoearelated mortality rates that were generated by a synthesis of several diff erent models. 15 In Mexico, the decline in allcause diarrhoea-related deaths after the introduction of rotavirus vaccine in 2006 8 is consistent with the number of annual rotavirus-related deaths estimated in our study, sug gesting that our method provides a reasonable estimate for rotavirus mortality. As more countries introduce rotavirus vaccine into their national immunisation programmes, the consistency of our estimates with recorded declines in mortality can be further assessed. Second, we assumed that the identifi cation of rotavirus infection in children admitted to hospital with diarrhoea was causally related to the illness. Although molecular methods often identify rotavirus in faecal specimens from healthy children, EIA, the method used in studies we reviewed, identifi es rotavirus in healthy children less often. 6 If asymptomatic infections are common, then our estimates of rotavirus-related mortality might be overestimates. Also, most studies included in our analysis tested stool specimens only for rotavirus and did not provide any information about potential co-infections. An ongoing multicountry study 26 assessing stool specimens from children with diarrhoea and from healthy children will provide more information into the frequency of asymptomatic and co-infections. Finally, countries that have published data on rotavirus-related admissions to hospital or that participated in the WHO-coordinated surveillance network might be systematically diff erent in their approach to treatment and care of children with diarrhoeal disease than countries without data, and thus could aff ect the proportion of diarrhoea-related admissions due to rotavirus. Similarly, hospitals that undertake rotavirus surveillance might not show the health-care seeking behaviour or management that is generalisable at the national level. Although some variation in methods in the studies we reviewed (eg, criteria for enrolment, timing of faecal specimen collection) could have aff ected our fi ndings and the number of studies in each group that met the selection criteria varied, we used a standard set of criteria to identify published reports and also included data from a network of sentinel hospital-based surveillance sites maintained by WHO that collects data with a standard protocol. Together, these studies provided data from 65 countries representing 69% of the worldwide population of children younger than 5 years. Additionally, the narrow 95% CIs of the rotavirus detection rates suggest that the proportion of diarrhoea due to rotavirus was relatively stable across groups.
Introduction of eff ective and available rotavirus vaccine could have a substantial eff ect on diarrhoea-related deaths worldwide. In 2009, WHO expanded its recommendation for rotavirus vaccine use to include all countries worldwide, with a particular emphasis on countries with high diarrhoea-related mortality. 4 However, so far, rotavirus vaccine has largely been introduced only in countries with low diarrhoea-related mortality. The effi cacy and eff ectiveness of rotavirus vaccines is lower in developingcountry than in developed-country settings [27] [28] [29] and therefore vaccine introduction should be in conjunction with eff orts to strengthen health-care systems. 4 Introduction of rotavirus vaccine in developing countries will probably have a substantial eff ect on worldwide rotavirus-related mortality because of the large number of diarrhoea-related deaths caused by rotavirus infection in developing countries. GAVI cofi nancing of vaccine introduction will play a key part in the reduction of mortality due to diarrhoea associated with rotavirus infection, because 95% of rotavirus-related deaths are in countries that are eligible for GAVI support. As more <10 deaths per 100 000 10-50 deaths per 100 000 50-100 deaths per 100 000 100-1000 deaths per 100 000 countries introduce rotavirus vaccine into their national immunisation programmes, continued surveil lance is crucial to update estimates of rotavirus-related mortality, including the age distribution of these deaths, and to measure the eff ect of vaccines and possible changes in the diversity of co-circulating rotaviruses.
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